Imugene Ltd
ASX:IMU

Watchlist Manager
Imugene Ltd Logo
Imugene Ltd
ASX:IMU
Watchlist
Price: 0.27 AUD -3.57% Market Closed
Market Cap: 59.3m AUD

EV/EBIT
Enterprise Value to EBIT

-0.2
Current
-7
Median
5.1
Industry
Higher than median
Lower than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
-0.2
=
Enterprise Value
27.9m AUD
/
EBIT
-132.5m AUD
Market Cap EV/EBIT
AU
Imugene Ltd
ASX:IMU
59.3m AUD -0.2
FR
Pharnext SCA
OTC:PNEXF
6T USD -192 566.9
US
Abbvie Inc
NYSE:ABBV
336.1B USD 22.7
US
Cyclo Therapeutics Inc
NASDAQ:CYTH
325.9B USD -13 207.5
US
Amgen Inc
NASDAQ:AMGN
164.8B USD 24.4
US
Gilead Sciences Inc
NASDAQ:GILD
144.7B USD 14.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120.7B USD 27.2
US
Epizyme Inc
F:EPE
94.1B EUR -564.5
AU
CSL Ltd
ASX:CSL
129.7B AUD 23.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
60.9B USD 13.6
US
Seagen Inc
F:SGT
39.3B EUR -60
EBIT Growth EV/EBIT to Growth
AU
Imugene Ltd
ASX:IMU
Average EV/EBIT: 21
Negative Multiple: -0.2
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 566.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.7
29%
0.8
US
Cyclo Therapeutics Inc
NASDAQ:CYTH
Negative Multiple: -13 207.5 N/A N/A
US
Amgen Inc
NASDAQ:AMGN
24.4
32%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
14.5
11%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
27.2
17%
1.6
US
E
Epizyme Inc
F:EPE
Negative Multiple: -564.5 N/A N/A
AU
CSL Ltd
ASX:CSL
23.7
14%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.6
11%
1.2
US
S
Seagen Inc
F:SGT
Negative Multiple: -60 N/A N/A

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
-0.2
2-Years Forward
EV/EBIT
-0.2
3-Years Forward
EV/EBIT
-0.4